Inloggen
E-mail
Wachtwoord
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

PLURISTEM THERAPEUTICS INC.

(PSTI)
uitgestelde koers. Vertraagde tijd Nasdaq - 18/06 22:00:01
3.94 USD   +0.51%
04/05PLURISTEM THERAPEUTICS INC.† : Alliance Global Partners handhaaft koopadvies
MM
2019PLURISTEM THERAPEUTICS : REVERSE SPLIT: 1 voor 10
FA
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtNieuwsAanbevelingen door analystenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť PLURISTEM THERAPEUTICS INC.
02/06PLURISTEM THERAPEUTICS INC† : Submission of Matters to a Vote of Security Holder..
AQ
25/05PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
25/05PLURISTEM THERAPEUTICS† : to Receive Ä20M Non-Dilutive Funding from the European..
AQ
06/05PLURISTEM THERAPEUTICS† : Management's Discussion and Analysis of Financial Cond..
AQ
04/05PLURISTEM THERAPEUTICS† : Analyst and investor call May 3, 2021- webcast & prese..
PU
04/05PLURISTEM THERAPEUTICS† : Analyst and investor call May 3, 2021- webcast
PU
04/05PLURISTEM THERAPEUTICS† : Analyst and investor call May 3, 2021- presentation
PU
03/05PLURISTEM THERAPEUTICS INC† : Regulation FD Disclosure, Financial Statements and..
AQ
03/05PLURISTEM THERAPEUTICS† : Analyst and investor call May 3, 2021- webcast, presen..
PU
29/04PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
29/04PLURISTEM THERAPEUTICS† : reports positive topline Phase I results in innovative..
AQ
26/03PLURISTEM THERAPEUTICS INC† : Changes in Registrant's Certifying Accountant, Fin..
AQ
08/02PLURISTEM THERAPEUTICS† : Management's Discussion and Analysis of Financial Cond..
AQ
03/02PLURISTEM THERAPEUTICS INC† : Entry into a Material Definitive Agreement, Financ..
AQ
03/02PLURISTEM THERAPEUTICS† : Announces $30 Million Registered Direct Offering
AQ
02/02PLURISTEM THERAPEUTICS INC.† : Announces $30 Million Registered Direct Offering
AQ
28/01PLURISTEM THERAPEUTICS† : Announces Uplisting to the Nasdaq Global Market
AQ
27/01PLURISTEM THERAPEUTICS† : Announces Uplisting to the Nasdaq Global Marketģ
AQ
06/01PLURISTEM THERAPEUTICS INC† : Change in Directors or Principal Officers (form 8-..
AQ
06/01PLURISTEM THERAPEUTICS† : Announces Appointments of Two Directors to Board
AQ
2020PLURISTEM THERAPEUTICS† : Enters Collaboration with Pharmaceutical Company Innov..
AQ
2020Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Ex..
GL
2020PLURISTEM THERAPEUTICS INC† : Regulation FD Disclosure, Other Events, Financial ..
AQ
2020Pluristem Announces DMC Recommendation Following Interim Analysis of its Phas..
GL
2020PLURISTEM THERAPEUTICS† : to Present Initial Results from Its Phase I HCT Study ..
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020PLURISTEM THERAPEUTICS† : to Present Initial Results from Its Phase I HCT Study ..
AQ
2020Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 ..
GL
2020PLURISTEM THERAPEUTICS† : Management's Discussion and Analysis of Financial Cond..
AQ
2020PLURISTEM THERAPEUTICS† : World Experts in Infectious Diseases and Critical Care..
AQ
2020PLURISTEM THERAPEUTICS† : World Experts in Infectious Diseases & Critical Care F..
AQ
2020World Experts in Infectious Diseases & Critical Care Form Pluristem's COVID-1..
GL
2020PLURISTEM THERAPEUTICS† : Announces Clearance to Move Forward with Enrollment fo..
AQ
2020PLURISTEM THERAPEUTICS† : Announces Clearance to Move Forward with Enrollment fo..
AQ
2020Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II i..
GL
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020PLURISTEM THERAPEUTICS† : Expands its Phase II COVID-19 European Clinical Trial ..
AQ
2020Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
GL
2020PLURISTEM THERAPEUTICS† : Abu Dhabi Stem Cells Center and Pluristem Unveil Joint..
AQ
2020PLURISTEM THERAPEUTICS† : Abu Dhabi Stem Cells Center and Pluristem Unveil Joint..
AQ
2020Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conf..
GL
2020PLURISTEM THERAPEUTICS† : CEO Issues Shareholder Update
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020PLURISTEM THERAPEUTICS† : CEO Issues Shareholder Update
AQ
2020Pluristem CEO Issues Shareholder Update
GL
2020PLURISTEM THERAPEUTICS† : Management's Discussion and Analysis of Financial Cond..
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Pat..
GL
2020Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
GL
2020Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Deve..
GL
2020PLURISTEM THERAPEUTICS† : expands its COVID-19 program to Europe, receives IEP c..
AQ
2020PLURISTEM THERAPEUTICS† : Expands Reach of Its COVID-19 Program to Europe and Re..
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to C..
GL
2020PLURISTEM THERAPEUTICS INC† : Entry into a Material Definitive Agreement, Financ..
AQ
2020Pluristem CEO Issues Shareholder Update on Clinical Programs
GL
2020PLURISTEM THERAPEUTICS INC† : Entry into a Material Definitive Agreement, Financ..
AQ
2020PLURISTEM THERAPEUTICS INC† : Change in Directors or Principal Officers, Submiss..
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020Pluristem Announces Activation of Clinical Sites and Commencement of Patient ..
GL
2020Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Developm..
GL
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patient..
GL
2020PLURISTEM THERAPEUTICS† : Management's Discussion and Analysis of Financial Cond..
AQ
2020PLURISTEM THERAPEUTICS† : U.S. FDA Clears Pluristem's IND Application for Phase ..
AQ
2020PLURISTEM THERAPEUTICS INC† : Other Events (form 8-K)
AQ
2020U.S. FDA Clears Pluristem's IND Application for Phase II COVID-19 Study
GL
2020PLURISTEM THERAPEUTICS INC† : Entry into a Material Definitive Agreement, Financ..
AQ
2020PLURISTEM THERAPEUTICS† : Announces Pricing of Its Registered Direct Offering fo..
AQ
2020PLURISTEM THERAPEUTICS† : Recaps Investor and Analyst Call Reviewing European In..
AQ
2020PLURISTEM THERAPEUTICS INC† : Creation of a Direct Financial Obligation or an Ob..
AQ
2020Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank's..
GL
2020EIB signs collaboration with Israel Innovation Authority and Ä50 million fina..
GL
2020PLURISTEM THERAPEUTICS† : The European Investment Bank, EU Delegation to Israel,..
AQ
2020PLURISTEM THERAPEUTICS† : Secures EUR50 Million Non-Dilutive Financing from the ..
AQ
1  2Volgende
Volgende evenement op PLURISTEM THERAPEUTICS INC.
13/07/21
Komende gebeurtenissen in de sector